• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

No consensus: Clinical trials wrestle with role of atropine in treating amblyopia

Article

Baltimore-Amblyopia is a relatively common problem in children, but there is no consensus on the best treatment. Recently, there has been increasing interest in using atropine drops instead of patching, but they are not FDA approved for that indication, said Michael X. Repka, MD.

Related Videos
Related Content
Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Intracortical Visual Prosthesis achieves 2 years of successful testing

Intracortical Visual Prosthesis achieves 2 years of successful testing

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
Using extracellular vesicles in the treatment of ocular diseases

Using extracellular vesicles in the treatment of ocular diseases

Article
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Article
© 2024 MJH Life Sciences

All rights reserved.